National Coverage Determination (NCD)

Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents

150.7

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
150.7
Manual Section Title
Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents
Version Number
1
Effective Date of this Version
09/27/1999

Description Information

Benefit Category
Physicians' Services


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Indications and Limitations of Coverage

The medical effectiveness of the above therapies has not been verified by scientifically controlled studies. Accordingly, reimbursement for these modalities should be denied on the ground that they are not reasonable and necessary as required by §1862(a)(1) of the Act.

Transmittal Information

Revision History
9/27/1999 - Issued decision memo maintaining national noncoverage policy.

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Additional Information

Other Versions
Title Version Effective Between
Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents 1 09/27/1999 - N/A You are here